Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.60 - $14.60
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.80M
Market Cap
$1.55B
Enterprise Value$396.51M
Total Cash (Recent Filing)$180.83M
Total Debt (Recent Filing)$5.96M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 06, 2025EPS Estimate
-0.45Last Dividend Ex-Date
Mar 28, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding106,667,435
10 Day Avg. Volume1,813,292
30 Day Avg. Volume1,795,379
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue-1.59K
Enterprise Value/Gross Profit-291.77
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$15.57Price Target Upside7.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe company presented positive 48-week long-term data from the Phase 2 HELIOS trial, showing sustained improvement in key health metrics.
Market OpportunityThe medically important PBH population could exceed the commonly cited 167,000 patients, indicating a larger market opportunity for avexitide.
Product PricingAvexitide’s orphan and breakthrough therapy designations suggest it can command premium pricing, estimated at $144,000 per patient annually.
Bears Say
Awareness And DiagnosisThe KOL’s discussion of the high unmet need and their patients’ cases strongly suggest that the PBH opportunity is real, though misdiagnosis and lack of awareness are prevalent.
Market CompetitionDespite the rise of GLP-1 receptor agonists, Roux-en-Y gastric bypass remains indispensable, highlighting a sustained need for treatments like avexitide.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $2.60 and its highest was $14.60 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $1.55B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2025 which is in 39 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Aug 07, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.444 by -$0.016.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.45.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 106,667,435 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.444. Following the earnings report the stock price went down -4.274%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.57 (7.23% Upside)
$15.57 (7.23% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 996.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
353.75%
12-Months-Change
Fundamentals
Return on Equity
-87.42%
Trailing 12-Months
Asset Growth
-41.41%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was overall positive, with significant progress reported in clinical trials and pipeline expansion. Financial management shows a strong cash position, although there are challenges related to market education and cash flow reduction.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$15.57
▲(7.23% Upside)
Technical Analysis
Benitec Biopharma
―
Checkpoint Therapeutics
―
Allogene Therapeutics
―
Eton Pharmaceuticals
―
Zenas BioPharma, Inc.
―
Ownership Overview
7.77% Insiders
6.43% Mutual Funds
42.27% Other Institutional Investors
30.85% Public Companies and
Individual Investors